Metabolomics profiling and neuroprotective effects of Lagerstroemia loudonii leaf extract and its kleptose Crysmeb®- stabilized loaded nanosuspension in seizure mice model
Rattachement africain : Égypte. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
This research was designed to explore the anti-epileptic action of the ethanolic leaf extract of Lagerstroemia loudonii (LLE) compared to the extract-loaded MβCD-stabilized nanosuspension (MβCD-NS). UPLC-ESI-QTOF -MS/MS analysis of LLE revealed the identification of 57 compounds; phenolics were the major recorded class. Nanosuspensions were prepared and examined; the particle size of the selected physically stable MβCD-NS was 445.8 ± 61.08 nm with a uniform size distribution and an almost spherical outline as shown by TEM. Based on the acute toxicity results, LLE or MβCD-NS was orally gavage at doses of 100 and 200 mg/kg. Convulsions were induced by maximum electric shock (MES, 35 mA, 3 s), and pentylenetetrazole (PTZ, 85 mg/kg i.p) in mice. MβCD-NS (200 mg/kg) demonstrated significant anticonvulsant effects, including complete protection% in MES study and low tonic convulsion score in PTZ-model. PTZ injection instigated locomotor deficits, oxidative and nitrosative insults, neuroinflammation, imbalance in brain neurotransmitters viz. dopamine, serotonin, norepinephrine, GABA, glutamate, and severe structural changes in the brain. However, LLE and MβCD-NS (200 mg/kg) ameliorated all these alterations through preserving antioxidant defense mechanisms by improving GSH content, and Nrf2 immuno-expression, as well as reducing MDA, NO, and GSSG levels in the brain. MβCD-NS restored the brain neurotransmitter levels that involved in the observed improvement in the animals' locomotor activity. The detected low TNF-α immuno-expression of the brain regions of the MβCD-NS group highlighted its anti-inflammatory action. In conclusion, MβCD-NS exhibited superior anti-epileptic potential by counteracting neuronal oxido-inflammatory damage, positioning it as a promising therapeutic strategy for epilepsy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Metabolomics profiling and neuroprotective effects of Lagerstroemia loudonii leaf extract and its kleptose Crysmeb®- stabilized loaded nanosuspension in seizure mice model
- Date Crossref
- 17/12/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Research Centre Chemistry of Natural Compounds Department Giza, Égypte (code pays fourni par la source)Structure de recherche
-
National Organization for Drug Control and Research Égypte (code pays fourni par la source)Structure de recherche
-
Cairo University Cairo University, Égypte (code pays fourni par la source)Université ou école supérieure
-
Medical Research and Clinical Studies Institute Pharmacology Department Giza, Égypte (pays nommé en fin d’affiliation)Structure de recherche
-
Physiology Department Giza, Égypte (pays nommé en fin d’affiliation)Institution
-
Faculty of Veterinary Medicine Pathology Department Cairo University, Égypte (pays nommé en fin d’affiliation)Université ou école supérieure
Chemistry of Natural Compounds Department — National Research Centre (Giza, Égypte), National Organization for Drug Control and Research (Égypte) et Cairo University (Cairo University, Égypte), avec 3 autres affiliations. Pays d’affiliation : Égypte.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.